Syntara (ASX:SNT) Receivables Turnover : 0.00 (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Syntara Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Syntara's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Syntara's average Accounts Receivable for the six months ended in Dec. 2023 was A$1.18 Mil.

Syntara Receivables Turnover Historical Data

The historical data trend for Syntara's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syntara Receivables Turnover Chart

Syntara Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Receivables Turnover

Get a 7-Day Free Trial

3.84

5.34

4.07

3.46

3.34

Syntara Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Receivables Turnover	Get a 7-Day Free Trial															1.85	0.47	0.26	1.06	-

Competitive Comparison of Syntara's Receivables Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Syntara's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syntara's Receivables Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syntara's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Syntara's Receivables Turnover falls into.

Syntara Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Syntara's Receivables Turnover for the fiscal year that ended in Jun. 2023 is calculated as

	Receivables Turnover (A: Jun. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Jun. 2023 )	/ (	(Accounts Receivable (A: Jun. 2022 )	+	Accounts Receivable (A: Jun. 2023 ))	/	count )
=	5.765	/ (	(2.464	+	0.985)	/	2 )
=	5.765	/	1.7245
=	3.34

Syntara's Receivables Turnover for the quarter that ended in Dec. 2023 is calculated as

	Receivables Turnover (Q: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2023 )	/ (	(Accounts Receivable (Q: Jun. 2023 )	+	Accounts Receivable (Q: Dec. 2023 ))	/	count )
=	0	/ (	(0.985	+	1.373)	/	2 )
=	0	/	1.179
=	N/A

Syntara (ASX:SNT) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Syntara Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Syntara's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Syntara (ASX:SNT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

UUDA:Germany

Address

20 Rodborough Road, Locked Bag 5015, Frenchs Forest, Sydney, NSW, AUS, 2086

Website

https://www.pharmaxis.com.au

Syntara Ltd Formerly Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.